Related by context. All words. (Click for frequent words.) 87 Phase III Clinical Trial 87 Phase IIb Trial 86 Meets Primary Endpoint 85 Clinical Trial Results 85 Patient Enrollment 84 Phase 2b Clinical Trial 83 Pivotal Trial 83 Completes Enrollment 83 Drug Candidate 82 Completes Patient Enrollment 82 Phase IIb Clinical Trial 82 Study Evaluating 82 Investigational Compound 81 Patients Treated With 81 Pivotal Study 81 Phase 2b Trial 81 Improves Survival 81 Receives Orphan Drug Designation 80 Pivotal Phase III 80 Patients Treated 80 Phase 2a Trial 80 NDA Submission 80 Clinical Trial Evaluating 80 Phase 2a Clinical Trial 79 II Clinical Trial 79 Pivotal Phase 79 Phase 2b Study 79 Phase III Trials 79 Lung Cancer Trial 79 Adjuvant Treatment 79 First Patient Enrolled 79 Well Tolerated 79 Previously Treated 78 Long Term Efficacy 78 Study Showed 78 Presents Positive 78 Gout Drug 78 Demonstrates Significant 78 Survival Benefit 78 Metastatic Colorectal Cancer 78 Initiate Phase III 78 Trial Evaluating 78 Antitumor Activity 78 Pivotal Trials 78 Oral Fingolimod 78 Osteoporosis Drug 78 Novel Oral 78 Lupus Drug 78 FDA Accepts 78 Demonstrates Positive 78 Single Dose 78 Combination Treatment 77 Initiates Phase III 77 Advanced Melanoma 77 Anti Tumor Activity 77 Preclinical Data 77 First Patient Dosed 77 Initiates Phase II 77 Migraine Drug 77 Initiate Phase 77 Improves Outcomes 77 Randomized Study 77 JAK Inhibitor 77 Prolongs Survival 77 Patients Enrolled 77 Pivotal Clinical Trial 77 Pooled Analysis 77 Submits NDA 77 Monotherapy 77 Combination REOLYSIN R 77 Investigational Treatment 77 Drug Fails 77 Renal Cell Carcinoma 77 Initiates Clinical Trial 77 Lung Cancer Drug 76 Arthritis Drug 76 IND Filing 76 Files IND 76 Successfully Completes Phase 76 Severe Sepsis 76 Improved Survival 76 Phase IIa Clinical Trial 76 Investigational Drug 76 Clinical Study 76 Metastatic Melanoma 76 Phase III Clinical Trials 76 Initiates Clinical 76 Shows Promising 76 Phase 1b Clinical Trial 76 Platelet Inhibition 76 Initiate Clinical Trial 76 Initiates Enrollment 76 Presents Preclinical Data 76 Brentuximab Vedotin SGN 76 Randomized Phase 76 Adjuvant Therapy 76 Granted Orphan Drug 76 Schizophrenia Drug 76 Present Preclinical Data 76 Autologous Stem Cell Transplantation 76 Patients Receiving 76 Significantly Improves 76 IND Application 76 Milestone Payment 76 Study Demonstrates 76 Newly Diagnosed Multiple Myeloma 75 FDA Approvals 75 Efficacy Trial 75 Confirmatory Phase 75 Generic Version 75 Relapsing Multiple Sclerosis 75 Rheumatoid Arthritis Patients 75 Cholesterol Lowering Drug 75 Achieves Primary Endpoint 75 Relapsed Multiple Myeloma 75 Significantly Reduced 75 Safinamide 75 FDA Clears 75 Shows Efficacy 75 Hormone Refractory Prostate Cancer 75 Drug Shows Promise 75 Randomized Double Blind 75 Disease Progression 75 Controlled Study 75 Mylan Receives Approval 75 Initiates Clinical Trials 75 Dose Escalation 75 Investigational Agent 75 Heart Failure Patients 75 Rheumatoid Arthritis Drug 75 FDA Approves 75 Hematological Malignancies 75 Epilepsy Drug 75 Sirolimus Eluting Stent 75 Phase III Pivotal 75 Tezampanel 75 Protease Inhibitor 75 Expanded Indication 75 Infected Patients 75 Pharmacokinetic Study 75 Psoriasis Drug 75 Demonstrates Efficacy 74 Begins Dosing 74 Treated Patients 74 Double Blind Placebo 74 HCV Protease Inhibitor 74 Is Well Tolerated 74 Initiates Phase 2b 74 Elderly Patients 74 Receives Milestone Payment 74 Lupus Nephritis 74 Statistically Significant 74 Cutaneous T 74 Preclinical Study 74 Receives Positive Opinion 74 Acute Ischemic Stroke 74 Previously Untreated 74 Randomized Clinical Trial 74 Prostate Cancer Vaccine 74 Interferon Alpha 74 Adjunctive Therapy 74 Positive Opinion 74 Dose Ranging Study 74 Pulmonary Arterial Hypertension 74 Phase Ib Clinical Trial 74 Transdermal Patch 74 Myeloma Patients 74 Patients Suffering 74 Receives Approvable Letter 74 Patient Enrolment 74 Blood Pressure Drug 74 Versus Placebo 74 Teva Provides Update 74 FDA Okays 74 Topline Results 74 Anticancer Activity 74 Cholesterol Drug 74 Significantly Improved 74 Subgroup Analysis 74 Significantly Reduces 74 Chronic Hepatitis C 74 Fast Track Status 74 Clinical Trial 74 Overactive Bladder 74 Spectrum Pharmaceuticals Announces 73 Oral Calcitonin 73 Relapsed Refractory 73 Demonstrates Potent 73 Combination Therapy 73 Demonstrated Significant 73 Hsp# Inhibitor 73 Data Suggest 73 Medoxomil 73 Demonstrates Potential 73 Advanced Colorectal Cancer 73 Receives FDA Clearance 73 Controlled Trial 73 Prospective Randomized 73 Improve Survival 73 Myelodysplastic Syndromes 73 Files Investigational 73 Plaque Psoriasis 73 Prostate Cancer Patients 73 Treatment Resistant 73 Clinical Outcome 73 Nilotinib 73 Relapsing Remitting Multiple Sclerosis 73 Clinical Efficacy 73 Unfractionated Heparin 73 Multiple Myeloma Patients 73 Novel Antibiotic 73 HER2 Positive Breast Cancer 73 Glatiramer Acetate 73 Initiates Phase 73 Vicriviroc 73 Oral Cladribine 73 Elagolix 73 Anti Tumor 73 Renal Cancer 73 PRN FDA Approves 73 Patient Treated 73 Tumor Growth 73 Vaccine Adjuvant 73 Anticancer Drug 73 Advanced Prostate Cancer 73 HDAC Inhibitor 72 Phase III Pivotal Trial 72 Low Dose 72 RNAi Therapeutic 72 Therapeutic Vaccine 72 Oral Formulation 72 Bosutinib 72 Stem Cell Treatment 72 Gene Therapy Trial 72 Appears Safe 72 Clinical Evaluation 72 HER2 Positive 72 VIVITROL ® 72 Clinical Trial Data 72 Node Positive 72 Sustained Reduction 72 Complicated Skin 72 Acute Attacks 72 SPRYCEL ® 72 Metastatic Prostate Cancer 72 Resistant Hypertension 72 Immunosuppression 72 Peginterferon 72 Randomized Controlled 72 Placebo Controlled Trial 72 Pediatric Patients 72 Colorectal Cancer Patients 72 Treating Chronic 72 Personalized Immunotherapy 72 Proves Effective 72 Statin Therapy 72 Combo Therapy 72 Gastric Cancer 72 Tolerability 72 JAK2 Inhibitor 72 Demonstrates Sustained 72 Slow Progression 72 Erectile Dysfunction Drug 72 Generic Versions 72 IIa Clinical Trial 72 Adjuvant Chemotherapy 72 Kinase Inhibitor 72 Chronic Hepatitis B 72 First Patient Treated 72 Announces FDA Clearance 72 Earns Milestone Payment 72 Disease Modifying 72 Treatment Naïve 72 Inflammatory Arthritis 72 Receives Orphan Drug 72 Confirms Efficacy 72 Prophylactic Treatment 72 Stent Restenosis 72 Seasonal Influenza Vaccine 72 Hypertensive Patients 72 RNAi Therapeutics 72 Patent Covering 72 Monoclonal Antibody 72 Receives Fast Track 72 Carboplatin Paclitaxel 72 Bivalirudin 72 Targeted Therapies 72 Metastatic Renal Cell Carcinoma 72 Enrolls First 71 Patients Undergoing 71 Knee Osteoarthritis 71 Glufosfamide 71 Breast Cancer Recurrence 71 Potent Antiviral Activity 71 Fungal Infections 71 Phase 2a Study 71 Collaborators Present 71 Reveals Positive 71 Biomarker Study 71 Postmenopausal Osteoporosis 71 Systemic Delivery 71 Novel Compound 71 Tyrosine Kinase Inhibitor 71 Neoadjuvant Chemotherapy 71 Advanced Renal Cell 71 Mouse Model 71 Eluting Stent 71 Placebo Controlled 71 Osteoporosis Treatment 71 Non Inferiority 71 Acute Myocardial Infarction 71 Hemodialysis Patients 71 Treatment Naive Patients 71 Metabolic Efficiency 71 Initiated Phase 71 Shows Promise Against 71 Pegloticase 71 Zoledronic Acid 71 Epoetin Alfa 71 Refractory Hodgkin Lymphoma 71 Shows Statistically Significant 71 ISTODAX ® 71 Molecular Diagnostic Test 71 Anti Clotting Drug 71 Placebo Controlled Study 71 Rotavirus Vaccine 71 Phase IIa Trial 71 Interferon Beta 71 Hormone Receptor Positive 71 Multicenter Randomized 71 Diabetic Nephropathy 71 Postmenopausal Women 71 Develop Novel 71 Oral Anticoagulant 71 Hepatitis C Patients 71 R lenalidomide 71 Plus Ribavirin 71 Acute Heart Failure 71 Ranolazine 71 Novel Inhibitor 71 Multicenter Study 71 FOLOTYN ® 71 Lung Cancer Survival 71 Tiotropium 71 Multicenter Trial 71 Receptor Agonist 71 Hepatitis B Vaccine 71 Telbivudine 71 FDA APPROVES 71 Chronic Myeloid Leukemia 71 Drug Combo 71 Naive Patients 71 Desvenlafaxine Succinate 71 Proven Effective 71 Announces Initiation 71 Bare Metal Stents 71 Diabetic Patients 71 Recombinant Human 71 Osteoporosis Drugs 71 Commences Phase 71 Lung Cancer Patients 71 Advanced Pancreatic Cancer 71 Dose Ranging 71 Venous Thromboembolism 71 Treatment Experienced 71 Efficacy Results 71 Chronic Lymphocytic Leukemia 71 Cardiovascular Events 71 Announces Presentation 71 Randomized Phase II 71 NICE Recommends 71 Slows Progression 70 Enrolling Patients 70 Immunotherapeutic 70 Randomized Phase III 70 Commence Phase 70 Mycophenolate Mofetil 70 FDA Clearance 70 Milestone Payments 70 Interferon Gamma 70 Bipolar Depression 70 Fondaparinux 70 Intravenous Formulation 70 Inhaled Insulin 70 Initiate Phase II 70 Gentium Announces 70 Ozarelix 70 Balloon Angioplasty 70 Ischemic Stroke 70 Nicotine Vaccine 70 Recurrent Breast Cancer 70 Humanized Anti 70 PDUFA Date 70 Radical Prostatectomy 70 Cardiovascular Outcomes 70 Gets FDA Clearance 70 Demonstrate Significant 70 Kidney Transplant Patients 70 Release Capsules 70 Orphan Status 70 Kidney Transplant Recipients 70 Investigational Oral 70 Fixed Dose 70 Oral Laquinimod 70 Presents Positive Preclinical 70 Romidepsin 70 Reduces Risk 70 Vascular Disrupting Agent 70 Schizophrenia Treatment 70 Shows Promise 70 Predict Risk 70 Pirfenidone 70 Atypical Hemolytic Uremic Syndrome 70 Phase IIIb 70 Kidney Function 70 Weight Loss Drug 70 Sirolimus Eluting 70 Romiplostim 70 Drug Eluting 70 Presents Preclinical 70 Microplasmin 70 Receives Complete Response 70 Hepatocellular Carcinoma 70 Therapeutic Potential 70 Enzyme Replacement Therapy 70 IL# PE#QQR 70 Pafuramidine 70 Stent Implantation 70 Soft Tissue Sarcoma 70 Blood Thinner 70 TO AVOID PREGNANCY WHILE 70 Inhalation Solution 70 Epratuzumab 70 Diabetic Neuropathy 70 Fewer Side Effects 70 Treatment Regimen 70 Pneumococcal Vaccine 70 Polymerase Inhibitor 70 Percutaneous Tibial Nerve Stimulation 70 Stent Thrombosis 70 TM Drug Eluting 70 Primary Endpoint 70 Cell Lymphoma 70 Antiviral Activity 70 Sustained Efficacy 70 Carotid Stenting 70 Sapacitabine 70 Aliskiren 70 Supplemental Biologics License Application 70 Drug Maker 70 Demonstrates Statistically Significant 70 Androgen Deprivation Therapy 70 Enoxaparin 70 Aflibercept 70 Castration Resistant Prostate Cancer 70 Novel Therapeutic 70 Effectively Treats 70 Meta Analysis 70 Extended Release 70 Treatment Naïve Patients 70 Extended Release Capsules 70 MEK Inhibitor 70 Completes Patient Enrolment 70 Prostate Cancer Treatment 70 Reports Preclinical Data 70 Metabolic Disorder 70 Drug Eluting Stent 70 Orally Active 70 Initiates Dosing 69 Emerging Therapies 69 Prognostic Significance 69 Patient Outcomes 69 Immunomedics Announces 69 Chronic Sinusitis 69 GATTEX TM 69 Symptom Relief 69 Drug Coated Stent 69 Sagent Pharmaceuticals Announces 69 Ridaforolimus 69 Augment TM 69 Universal Flu Vaccine 69 Eculizumab 69 Gene Variant 69 Cethromycin 69 FDA Approves Drug 69 Drug Eluting Stents 69 Taro Receives 69 Relapsed 69 Completes Dosing 69 Showed Significant 69 Preclinical Models 69 Left Ventricular Hypertrophy 69 refractory chronic lymphocytic 69 Multicenter Phase 69 Hypercholesterolemia 69 Multiple Ascending Dose 69 Hematological Cancers 69 Anticancer Compound 69 Replacement Therapy 69 Benign Prostatic Hyperplasia 69 Treatment Shows Promise 69 Embolic Protection 69 Randomized Clinical Trials 69 Neoadjuvant 69 Ambrisentan 69 Cypher Sirolimus 69 Liver Metastases 69 Newly Diagnosed 69 Randomized Double blind 69 Submits Biologics License Application 69 Cholesterol Drugs 69 Bone Metastases 69 Inhaled Corticosteroids 69 Improve Outcomes 69 ORENCIA ® 69 Treatment Reduces 69 Stakeholder Opinions 69 Pharmacokinetics PK 69 Announces Poster Presentations 69 Announces Tentative Approval 69 Beta Blocker 69 Pivotal Phase II 69 Follicular Lymphoma 69 Malaria Vaccine 69 Cell Transplants 69 Acute Coronary Syndromes 69 Successfully Treats 69 Vaccine Candidate 69 Bazedoxifene 69 Testosterone Gel 69 Valsartan 69 CCX# B 69 Vaginal Gel 69 Novel Mechanism 69 Anemia Drug 69 Small Molecule 69 dependent kinase inhibitor 69 Successfully Treated 69 Breast Cancer Treatment 69 alfa 2a 69 FDA Approval 69 Therapy Evaluation 69 Efficacious 69 Receives SFDA Approval 69 Novel Treatments 69 rasagiline tablets 69 Adalimumab 69 Pazopanib 69 Renal Anemia 69 Chronic Heart Failure 69 Golimumab 69 Clinical Study Shows 69 Dasatinib 69 Zenvia Phase III 69 Diamyd Medical Diamyd 69 Drug Resistant 69 Pegylated 69 Bucindolol 69 Randomized Trials 69 Submits Application 69 Randomized Double Blind Placebo 69 Milestone Payment From 69 PEGylated Fab fragment 69 Cancer Treatments 69 Lowers Risk 69 Hepatitis C Treatment 69 oral prodrug 69 Therapeutic Antibody 69 Telaprevir VX 69 BioSante Pharmaceuticals Announces 69 Guidelines Recommend 69 Aloxi ® 69 Smallpox Vaccine 69 Intravitreal 69 Therapy Reduces 69 Antidepressant Drug 69 Cites Positive 68 Liver Failure 68 Treatment Naive 68 Diabetic Foot Ulcer 68 Febuxostat 68 Xcytrin R 68 Receives Marketing Authorization 68 See CLINICAL PHARMACOLOGY 68 Therapy Improves 68 DOR BioPharma Announces 68 Insulin Glargine 68 Pegylated Liposomal Doxorubicin 68 Combination Clinical Trial 68 Paclitaxel Carboplatin 68 Viral Suppression 68 STELARA TM 68 C1 Inhibitor 68 Clostridium difficile Infection 68 Myelodysplastic Syndrome MDS 68 Regenerative Cells 68 sunitinib Sutent 68 Orphan Drug Status 68 Sangamo BioSciences Announces 68 TRANSDUR ™ 68 Newly Diagnosed Patients 68 Melphalan 68 cetuximab Erbitux R 68 PEGylated anti 68 Invasive Fungal Infections 68 Paroxysmal Atrial Fibrillation 68 Therapeutic Efficacy 68 Cocaine Addiction 68 Interferon Alfa 68 Test Detects 68 Laryngeal Cancer 68 Brain Metastases 68 Optimer Pharma 68 Minimally Invasive Treatment 68 Bevacizumab 68 Irinotecan 68 Non Invasive Treatment 68 Cardiogenic Shock 68 Serious Infections 68 Begin Clinical Trials 68 Obese Patients 68 Prospective Multicenter 68 Chemotherapy Regimen 68 Complete Remission 68 Ofatumumab 68 Transplant Patients 68 Dose Escalation Study 68 Peginterferon Alfa 2a 68 Lung Cancers 68 Long Term Outcomes 68 Submits Response 68 Interferon beta 1a 68 Stomach Cancer 68 BioElectronics Announces 68 Left Ventricular 68 Posaconazole 68 Anthracycline 68 Therapy Shows Promise 68 Oral Mucositis 68 Preclinical Efficacy 68 Randomized Evaluation 68 Enlarged Prostate 68 Receptor Antagonist 68 Inhaled Liposomal Ciprofloxacin 68 Anticancer Agent 68 Increases Risk 68 Malignant Melanoma 68 Syncria R 68 Phase IIIb clinical 68 Cancer Patients Treated 68 Significant Improvement 68 Unstable Angina 68 Archexin 68 SUTENT ® 68 Ocrelizumab 68 Lenalidomide 68 Million Milestone Payment 68 Dose Finding 68 Dupuytren Contracture 68 Cinacalcet 68 Tipranavir 68 Statin Drugs 68 Less Invasive 68 Gene Mutation 68 Acute Migraine 68 Inhibits 68 Clinical Trial Enrollment 68 Unresectable 68 Poniard Pharmaceuticals Announces 68 Long Term Survival 68 Peginterferon Alfa 2b 68 Clolar ® 68 Therapeutic Vaccines 68 Glucose Control 68 Anti TNF 68 Atypical Antipsychotics 68 Orthostatic Hypotension 68 Tacrolimus 68 Tesetaxel 68 Pralatrexate 68 Myoblast 68 Testosterone Patch 68 Chemoradiation 68 Oral Spray 68 phase IIb trial 68 Receive Milestone Payment 68 Ovarian Cancer Patients 68 Endometrial Cancer 68 Asthma Treatment 68 Multicenter 68 Sandostatin R 68 Fabry Disease 68 Heart Transplant Recipients 68 Inhaled Nitric Oxide 68 Study Evaluates 68 PEGINTRON TM 68 KRN# 68 Artery Disease 68 Gene Linked 68 Hormone Therapy 68 VIVUS Announces 68 Pharmacokinetic 68 Fracture Risk 68 Synthetic Peptide 68 Solid Tumors 68 dasatinib Sprycel ® 68 Amrubicin 68 Inflammatory Markers 68 atypical Hemolytic Uremic Syndrome 68 Parathyroid Hormone 68 Drug Eluting Coronary Stent 68 Controlled Clinical Trial 68 Immunosuppressant 68 Announces Publication 68 CYPHER R Sirolimus Eluting 68 Anti Inflammatory Drug 68 Pharmaceuticals Initiates 68 Pemetrexed 68 Bone Fracture 68 Pegylated Interferon 68 Study Confirms 68 SABER ™ 68 Abciximab 67 Licenses Novel 67 Injection Site 67 BARACLUDE R 67 Treat Anemia 67 Diagnostic Criteria 67 evaluating tivozanib 67 Gastrointestinal Stromal Tumors 67 Reduced Incidence 67 Reduced Risk 67 Prognostic Value 67 ST Segment Elevation 67 Breast Cancer Patients 67 Receives Tentative Approval 67 FUSILEV ® 67 Vitro Activity 67 Alemtuzumab 67 Severe Asthma 67 Heartburn Drugs 67 Beneficial Effects 67 evaluating picoplatin 67 Darbepoetin Alfa 67 Fulvestrant 67 Tesamorelin 67 Announce License Agreement 67 BRIM3 67 Progenitor Cells 67 Iloperidone 67 Premenopausal Women 67 Companion Diagnostic 67 Mg Usa 67 induced macular edema 67 Sipuleucel T 67 Adenoma 67 Certolizumab 67 Cancer Vaccine 67 Spinal Fusion 67 Calcium Acetate 67 Paliperidone Palmitate 67 Systemic Sclerosis 67 Hepatitis C Virus 67 Influenza Vaccine Production 67 Capecitabine 67 Anti CD# Antibody 67 Cetrorelix 67 Treating Heart Failure 67 Denufosol 67 pralatrexate injection folate analogue 67 REG1 Anticoagulation System 67 Allergic Rhinitis 67 HP Acthar Gel repository 67 Eszopiclone 67 Hepatitis C Genotype 67 Shown Effective 67 Oncology Compounds 67 Total Knee Arthroplasty 67 Increased Mortality 67 Psoriasis Patients 67 Blood Pressure Lowering 67 Antiplatelet Therapy 67 Effective Than 67 Prolongs Life 67 Radiofrequency Ablation 67 Boosts Survival 67 Genetic Disorder 67 Aztreonam Lysine 67 Improves Quality 67 Deforolimus 67 SinuNase TM 67 Clinical Outcomes 67 Phase Ib II 67 Advanced Ovarian Cancer 67 Topical Treatment 67 Mayo Clinic Study Finds 67 Bortezomib 67 Aneurysm Repair 67 Telik Announces 67 Levoleucovorin 67 Catheter Ablation 67 Significant Reduction 67 Dual Antiplatelet Therapy 67 methylnaltrexone bromide 67 Renal Function 67 Drug Prevents 67 TNF Blockers 67 Phospholipase A2 67 Etanercept 67 Maleate 67 Mg Uk 67 ORLive Presents 67 Patent Issued 67 Relapsed Refractory Aggressive 67 Capsules CII 67 Abstract Accepted 67 Treatment Naive HIV 67 Antiepileptic Drug 67 Vitrasert R 67 Adverse Event 67 Advanced Gastric Cancer 67 Novel Therapies 67 Therapeutic Competitors Companies 67 Civacir 67 Achieves Milestone 67 Coronary Stent 67 Protein Linked 67 Tuberculosis Vaccine 67 Renal Impairment 67 Increased Risk 67 Localized Prostate Cancer 67 Shingles Vaccine 67 Onyx Pharmaceuticals Announces 67 Reports Positive 67 TRANSDUR ® 67 Synta Announces 67 Antiviral Drugs 67 Zorbtive TM 67 Genasense R 67 Malignant Glioma 67 Meet Primary Endpoint 67 Genes Predict 67 fosbretabulin 67 Hematopoietic Stem Cell Transplantation 67 Patient Accrual 67 ST Elevation Myocardial 67 Helps Predict 67 TB Vaccine 67 Antipsychotic 67 Randomized Controlled Trial 67 Avian Flu Vaccine 67 Myelofibrosis 67 Cardiac Resynchronization 67 Submits Supplemental 67 BRIM2 67 By JENNIFER LEARN 67 Myocet 67 Oral Insulin 67 Experimental Vaccine 67 Tigecycline 67 Secondary Hyperparathyroidism 67 FDA Approvable Letter 67 Radioimmunotherapy 67 Partial Onset Seizures 67 Antiplatelet 67 Non Responders 67 Insulin Resistance 67 EntreMed Presents 67 Ebola Vaccine 67 LibiGel ® 67 PANVAC VF 67 Cognitive Impairment 67 Osteoarthritis Patients 67 sapropterin dihydrochloride 67 EVIZON TM 67 Critical Limb Ischemia 67 Diet Pill 67 Marketing Authorisation Application 67 Trodusquemine MSI 67 Remission Maintenance 67 Diabetic Macular Edema 67 Gene Variation 67 Dialysis Patients 67 Double Blind Randomized 67 novel orally inhaled 67 Genes Linked 67 albiglutide 67 Treat Heart Failure 67 Methylnaltrexone 67 Daclizumab 67 Pharmacyclics Announces 67 Antipsychotic Drug 67 Contrast Agent 67 Endovascular Treatment 67 CHMP Opinion 67 Guidelines Issued 67 Post Operative 67 Nebulized 67 Commercialize 66 Angiogenic 66 Dose Response 66 Tocilizumab 66 Vitaxin 66 IN PATIENTS WITH 66 Flamel Technologies Announces 66 Phase #b/#a clinical 66 Announces Positive 66 Skeletal Muscle 66 Significant Improvements 66 Kinase Inhibitors 66 Azacitidine 66 Recurrent Glioblastoma 66 Diabetic Ulcers 66 multicenter multinational 66 ThermoDox R 66 Refractory Angina 66 Antithrombin 66 Non Invasive 66 Drug Eluting Stent System 66 Generic Lovenox 66 Regeneron Pharma 66 Receives CE Marking 66 Submits IND 66 Antigen Specific 66 Analytical Tool 66 Endeavor Drug Eluting 66 Premature Infants 66 Study Proves 66 Successful Completion 66 Rivaroxaban 66 ACE Inhibitors 66 Collaborators Publish 66 Tablet Formulation 66 Upcoming Milestones 66 Inflammatory Diseases 66 Uterine Fibroid Embolization 66 Decitabine 66 Hospital Acquired Pneumonia 66 cell lymphoma CTCL 66 Advanced Solid Tumors 66 Extended Release Formulation 66 Statistical Significance 66 Simulect 66 dextromethorphan quinidine 66 Randomised 66 Stem Cell Transplants 66 Inhalation Aerosol 66 Tumor Targeting 66 Cell Lung Cancer 66 Aggressive Prostate Cancer 66 Study Validates 66 Biogen Genentech 66 Randomized Controlled Trials 66 Renal Cell Cancer 66 PHASE III 66 Generic Version Of 66 TRANSFORMS 66 Anticoagulant 66 GW# [003] 66 Neuroprotective Effects 66 Prospective Randomized Trial 66 Acute Myocardial 66 Levels Linked 66 Being Studied 66 Critically Ill Patients 66 Fluorouracil 66 Abiraterone Acetate 66 Drug Coated Stents 66 DIRECT Trial 66 Omacetaxine 66 Sunesis Pharma 66 Anti Inflammatory 66 Atopic Dermatitis 66 Dapagliflozin 66 Protease Inhibitors 66 familial amyloidotic polyneuropathy FAP 66 Study Shows Benefits 66 Cloretazine ® 66 Resubmission 66 docetaxel Taxotere ® 66 Adefovir 66 Nuvelo Announces 66 Oral Interferon 66 phase IIb clinical 66 Estrogen Therapy 66 Nitazoxanide 66 Blood Cancers 66 vapreotide acetate 66 Factor Xa Inhibitor 66 Relapsed Refractory Multiple Myeloma 66 Launches Generic Version 66 Migraine Pain 66 5 FU leucovorin 66 Insulin Pen 66 ENDEAVOR IV 66 Vildagliptin 66 Novel Compounds 66 Anti Angiogenesis 66 Aurora Kinase